CRP and COVID-19: Multiple monoclonal antibodies and immunomodulatory compounds were evaluated in COVID-19 infection (Table 6), driven by the aim to impact on COVID-19 associated systemic inflammation that can be associated with heightened cytokine release, as indicated by elevated blood levels of IL-6, C-reactive protein (CRP), D-dimer and ferritin [221,222,223,224].